西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2014年
11期
17-21
,共5页
子宫腺肌病%异位和在位内膜%组织形态学%血管内皮生长因子%内皮抑素%微血管密度%蒲灵化瘀止痛方
子宮腺肌病%異位和在位內膜%組織形態學%血管內皮生長因子%內皮抑素%微血管密度%蒲靈化瘀止痛方
자궁선기병%이위화재위내막%조직형태학%혈관내피생장인자%내피억소%미혈관밀도%포령화어지통방
adenomyosis%ectopic and eutopic endometrium%histomorphology%vascular endothelial growth factor%endostatin%microvessel density%PuLing HuaYu ZhiTong prescription
目的：探讨蒲灵化瘀止痛方对子宫腺肌病(Adenomyosis，ADM)小鼠异位及在位内膜血管内皮生长因子(VEGF)、内皮抑素(ENS)、微血管密度(MVD)表达的影响，从血管生成相关因子的角度揭示蒲灵化瘀止痛方治疗ADM的作用机理。方法：造模饲养3个月建立小鼠ADM模型。将ADM小鼠随机分为蒲灵化瘀止痛方高、中、低剂量组，丹莪妇康煎膏组，孕三烯酮组，模型组，空白组，连续给药12周后，采用HE染色法观察不同组子宫内膜腺体与间质侵入子宫肌层的程度；采用免疫组化SP法染色检测异位和在位子宫内膜的VEGF、ENS的表达，并通过CD31标记异位子宫内膜血管内皮细胞，测定其MVD。结果：蒲灵化瘀止痛方高、中剂量组能降低模型小鼠异位和在位内膜VEGF的表达(P＜0.01)，降低模型组小鼠异位内膜VEGF/ENS的比值(P＜0.01)，有下调模型小鼠在位内膜VEGF/ENS比值的趋势。结论：蒲灵化瘀止痛方减少经量的机制可能是抑制在位内膜血管生成，减少在位内膜血管数量；蒲灵化瘀止痛方缩小病灶、减轻痛经程度的机制可能是抑制异位内膜血管生成，减少异位内膜血管数量。
目的：探討蒲靈化瘀止痛方對子宮腺肌病(Adenomyosis，ADM)小鼠異位及在位內膜血管內皮生長因子(VEGF)、內皮抑素(ENS)、微血管密度(MVD)錶達的影響，從血管生成相關因子的角度揭示蒲靈化瘀止痛方治療ADM的作用機理。方法：造模飼養3箇月建立小鼠ADM模型。將ADM小鼠隨機分為蒲靈化瘀止痛方高、中、低劑量組，丹莪婦康煎膏組，孕三烯酮組，模型組，空白組，連續給藥12週後，採用HE染色法觀察不同組子宮內膜腺體與間質侵入子宮肌層的程度；採用免疫組化SP法染色檢測異位和在位子宮內膜的VEGF、ENS的錶達，併通過CD31標記異位子宮內膜血管內皮細胞，測定其MVD。結果：蒲靈化瘀止痛方高、中劑量組能降低模型小鼠異位和在位內膜VEGF的錶達(P＜0.01)，降低模型組小鼠異位內膜VEGF/ENS的比值(P＜0.01)，有下調模型小鼠在位內膜VEGF/ENS比值的趨勢。結論：蒲靈化瘀止痛方減少經量的機製可能是抑製在位內膜血管生成，減少在位內膜血管數量；蒲靈化瘀止痛方縮小病竈、減輕痛經程度的機製可能是抑製異位內膜血管生成，減少異位內膜血管數量。
목적：탐토포령화어지통방대자궁선기병(Adenomyosis，ADM)소서이위급재위내막혈관내피생장인자(VEGF)、내피억소(ENS)、미혈관밀도(MVD)표체적영향，종혈관생성상관인자적각도게시포령화어지통방치료ADM적작용궤리。방법：조모사양3개월건립소서ADM모형。장ADM소서수궤분위포령화어지통방고、중、저제량조，단아부강전고조，잉삼희동조，모형조，공백조，련속급약12주후，채용HE염색법관찰불동조자궁내막선체여간질침입자궁기층적정도；채용면역조화SP법염색검측이위화재위자궁내막적VEGF、ENS적표체，병통과CD31표기이위자궁내막혈관내피세포，측정기MVD。결과：포령화어지통방고、중제량조능강저모형소서이위화재위내막VEGF적표체(P＜0.01)，강저모형조소서이위내막VEGF/ENS적비치(P＜0.01)，유하조모형소서재위내막VEGF/ENS비치적추세。결론：포령화어지통방감소경량적궤제가능시억제재위내막혈관생성，감소재위내막혈관수량；포령화어지통방축소병조、감경통경정도적궤제가능시억제이위내막혈관생성，감소이위내막혈관수량。
Objective: To reveal the mechanism of PuLing HuaYu ZhiTong prescription in treating adenomyosis (ADM) from the angles of angiogenesis-related factors by exploring the influence of PuLing HuaYu ZhiTong prescription on the expressions of vascular endothelial growth factor (VEGF), endostatin (ENS) and microvessel density (MVD) in ectopic and eutopic endometrium of mice with ADM. Methods:ADM mice models were prepared by feeding in three months. ADM mice were randomly allocated to high, moderate and low dose groups of PuLing HuaYu ZhiTong prescription, DanEFuKang extract group, gestrinone group, the model group and the blank group, after medicating for 12 consecutive weeks, the degrees of endometrial gland and stroma invading myometrium in different groups were observed by HE staining method;the expressions of VEGF and ENS in ectopic and eutopic endometrium detected by immunohistochemical SP staining method, and MVD measured by marking vascular endothelial cells of ectopic endometrium with CD31. Results:PuLing HuaYu ZhiTong prescription in high and moderate doses could lower the expressions of VEGF in ectopic and eutopic endometrium (P<0.01), it could decrease the ratio of VEGF/ENS of ectopic endometrium of the mice in the model group (P<0.01), and showed the trend of lowering the ratio of VEGF/ENS in eutopic endometrium of the mice. Conclusion:PuLing HuaYu ZhiTong prescription reducing menstrual blood volume is through inhibiting the angiogenesis of eutopic endometrium and decreasing the number of blood vessels in eutopic endometrium. The mechanism of PuLing HuaYu ZhiTong prescription narrowing the focus and alleviating the dysmenorrheal is by inhibiting the angiogenesis of ectopic endometrium and reducing the number of blood vessels in ectopic endometrium.
